Bevacizumab versus Ranibizumab for AMD

被引：39
|
作者：
Rosenfeld, Philip J. [1 ]
机构：
[1] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2011年 / 364卷 / 20期
关键词：
D O I：
10.1056/NEJMe1103334
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1966 / 1967
页数：2
相关论文
共 50 条
  • [1] Lucentis (Ranibizumab) versus Avastin (Bevacizumab) for CNV/AMD
    Naomi, Fischer
    Rodrigo, Jung
    Gadi, Heilweil
    David, Varssano
    Michaella, Goldstein
    Adiel, Barak
    Anat, Loewenstein
    [J]. 8TH INTERNATIONAL SYMPOSIUM ON OCULAR PHARMACOLOGY AND THERAPEUTICS - ISOPT, 2009, : 65 - 68
  • [2] Ranibizumab and Bevacizumab for AMD REPLY
    Martin, Daniel F.
    Maguire, Maureen G.
    Fine, Stuart L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (23): : 2237 - 2237
  • [3] Bevacizumab: as effective as ranibizumab for AMD, but safe?
    [J]. Reactions Weekly, 2012, 1404 (1) : 5 - 5
  • [4] Aflibercept for AMD patients treated unsuccessfully with Ranibizumab and Bevacizumab
    Pappas, George Dimitris
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [5] Bevacizumab less costly, just as safe as ranibizumab in AMD
    [J]. Reactions Weekly, 2014, 1519 (1) : 12 - 12
  • [6] Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab
    Cho, Hyung
    Shah, Chirag P.
    Weber, Marissa
    Heier, Jeffrey S.
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2013, 97 (08) : 1032 - 1035
  • [7] Bevacizumab versus ranibizumab: A draw?
    Souied, E. H.
    Cohen, S. Y.
    Kodjikian, L.
    [J]. JOURNAL FRANCAIS D OPHTALMOLOGIE, 2012, 35 (02): : 79 - 81
  • [8] BEVACIZUMAB VERSUS RANIBIZUMAB FOR AGE-RELATED MACULAR DEGENERATION (AMD): A BUDGET IMPACT ANALYSIS
    Zimmermann, I
    Schneiders, R. E.
    Mosca, M.
    Alexandre, R. F.
    do Nascimento Jr, J. M.
    Gadelha, C. A.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A569 - A569
  • [9] Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD
    Scholler, Andreas
    Richter-Mueksch, Sibylla
    Weingessel, Birgit
    Vecsei-Marlovits, Pia-Veronika
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2014, 126 (11-12) : 355 - 359
  • [10] Effects of bevacizumab, ranibizumab, and aflibercept on phagocytic properties in human RPE cybrids with AMD versus normal mitochondria
    Vo, Thomas A.
    Abedi, Sina
    Schneider, Kevin
    Chwa, Marilyn
    Kenney, M. Cristina
    [J]. EXPERIMENTAL EYE RESEARCH, 2018, 177 : 112 - 116
12345